Norvium Biosciences

Norvium Biosciences is an Oxford-based biotechnology company dedicated to discovering and developing transformative medicines for neurodegenerative disorders, with a primary focus on Parkinson's disease. The company's approach centers on restoring mitochondrial function and promoting mitophagy to address the underlying cellular pathology of these conditions. Spun out from the University of Oxford, Norvium utilizes advanced disease modeling and small molecule chemistry to target specific mitochondrial pathways. By focusing on precision medicine, the company aims to deliver therapies tailored to patient subsets most likely to benefit from mitochondrial restoration. Norvium is backed by leading life science investors and maintains strong ties to world-class academic research.